Allogenic cell secretions - Cambium Bio
Alternative Names: MSC derived secretome - Cambium Bio; MSC- derived bioactive secretome - Cambium Bio; Secretome - Cambium Bio; SygenusLatest Information Update: 21 Jun 2024
Price :
$50 *
At a glance
- Originator Regeneus ltd
- Developer Cambium Bio
- Class Analgesics; Anti-inflammatories; Antiacnes; Proteins; Skin disorder therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Lichen planus; Neuropathic pain; Wounds
- No development reported Acne
Most Recent Events
- 20 Jul 2023 Preclinical development is ongoing for Neuropathic pain in Australia (Regeneus pipeline, July 2023)
- 28 Feb 2023 No recent reports of development identified for clinical-Phase-Unknown development in Acne in Australia (Topical, Gel)
- 28 Feb 2023 No recent reports of development identified for preclinical development in Neuropathic-pain in Australia (Topical, Gel)